These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25587812)

  • 41. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct oral anticoagulants: to switch or not to switch?
    Lugthart S; Leebeek FW
    Neth J Med; 2015 Oct; 73(8):359-61. PubMed ID: 26478544
    [No Abstract]   [Full Text] [Related]  

  • 43. Non-vitamin K antagonist oral anticoagulants (NOACs) in the cardiac catherisation laboratory: Friends or Foes?
    Htun NM; Peter K
    Thromb Haemost; 2015 Aug; 114(2):214-6. PubMed ID: 25995026
    [No Abstract]   [Full Text] [Related]  

  • 44. Maintenance electroconvulsive therapy in a patient with multiple system atrophy and bipolar disorder.
    Obiora O; McCormick LM; Karim Y; Gonzales P; Beeghly J
    J ECT; 2012 Jun; 28(2):e1-2. PubMed ID: 22622294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivaroxaban for Left Ventricular Thrombus.
    Yassin AS; Abubakar H; Mishra T; Adam O; Hartman M; Pahuja M; Shokr M
    Am J Ther; 2019; 26(4):e511-e515. PubMed ID: 29420319
    [No Abstract]   [Full Text] [Related]  

  • 46. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
    Sciascia S; Breen K; Hunt BJ
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
    [No Abstract]   [Full Text] [Related]  

  • 48. Rivaroxaban Used for Treatment of a Left Ventricular Thrombus in a Patient With Nonischemic Cardiomyopathy.
    Abubakar H; Yassin AS; Shokr M
    Am J Ther; 2018; 25(6):e706-e709. PubMed ID: 29324466
    [No Abstract]   [Full Text] [Related]  

  • 49. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
    Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
    Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Isolated hemopericardium associated with rivaroxaban: first case report.
    Shivamurthy P; Brar N; Therrien ML
    Pharmacotherapy; 2014 Sep; 34(9):e169-72. PubMed ID: 25074401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Electroconvulsive therapy in a geriatric patient with normal pressure hydrocephalus without a shunt.
    Hermida AP; Job G; Tang Y
    J ECT; 2014 Dec; 30(4):e55-6. PubMed ID: 25265148
    [No Abstract]   [Full Text] [Related]  

  • 52. Successful Treatment With Electroconvulsive Therapy of a Patient With Bipolar Disorder and a 7-mm Cerebral Aneurysm.
    Toprak M; Wilkinson ST; Ostroff RB
    J ECT; 2017 Mar; 33(1):e8. PubMed ID: 28072662
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation.
    Santarpia G; Curcio A; Sibilio G; Indolfi C
    Circ J; 2015; 79(5):914-23. PubMed ID: 25833178
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of rivaroxaban in left ventricular thrombi.
    Abdelnaby M; Almaghraby A; Abdelkarim O; Saleh Y; Hammad B; Badran H
    Anatol J Cardiol; 2019 Jan; 21(1):47-50. PubMed ID: 30587707
    [No Abstract]   [Full Text] [Related]  

  • 55. Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
    Lefaucheur R; Le Goff F; Gaillon G; Triquenot-Bagan A; Maltête D
    Presse Med; 2015 Nov; 44(11):1203-4. PubMed ID: 26433836
    [No Abstract]   [Full Text] [Related]  

  • 56. Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system.
    Ishibashi Y; Matsui T; Fukami K; Ueda S; Okuda S; Yamagishi S
    Thromb Res; 2015 Apr; 135(4):770-3. PubMed ID: 25636461
    [No Abstract]   [Full Text] [Related]  

  • 57. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome.
    Góralczyk T; Iwaniec T; Wypasek E; Undas A
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):473-5. PubMed ID: 25402189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Electroconvulsive therapy. I. Effectiveness and side effects of electroconvulsive therapy].
    Sauer H; Lauter H
    Nervenarzt; 1987 Apr; 58(4):201-9. PubMed ID: 3587453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.